River & Mercantile Asset Management LLP cut its stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 33.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,810 shares of the biopharmaceutical company’s stock after selling 1,910 shares during the period. River & Mercantile Asset Management LLP’s holdings in Alexion Pharmaceuticals were worth $464,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Morgan Stanley increased its position in Alexion Pharmaceuticals by 112.0% in the first quarter. Morgan Stanley now owns 585,482 shares of the biopharmaceutical company’s stock valued at $70,983,000 after buying an additional 309,299 shares in the last quarter. DekaBank Deutsche Girozentrale increased its position in Alexion Pharmaceuticals by 18.2% in the first quarter. DekaBank Deutsche Girozentrale now owns 114,493 shares of the biopharmaceutical company’s stock valued at $14,017,000 after buying an additional 17,642 shares in the last quarter. Sumitomo Mitsui Asset Management Company LTD increased its position in Alexion Pharmaceuticals by 10.9% in the first quarter. Sumitomo Mitsui Asset Management Company LTD now owns 18,859 shares of the biopharmaceutical company’s stock valued at $2,286,000 after buying an additional 1,849 shares in the last quarter. Baird Financial Group Inc. increased its position in Alexion Pharmaceuticals by 219.0% in the first quarter. Baird Financial Group Inc. now owns 14,606 shares of the biopharmaceutical company’s stock valued at $1,771,000 after buying an additional 10,028 shares in the last quarter. Finally, LS Investment Advisors LLC increased its position in Alexion Pharmaceuticals by 13.0% in the first quarter. LS Investment Advisors LLC now owns 6,131 shares of the biopharmaceutical company’s stock valued at $743,000 after buying an additional 706 shares in the last quarter. Hedge funds and other institutional investors own 94.26% of the company’s stock.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) opened at 139.02 on Tuesday. The company has a market capitalization of $31.03 billion, a PE ratio of 60.29 and a beta of 1.41. The stock has a 50 day moving average price of $132.60 and a 200-day moving average price of $123.39. Alexion Pharmaceuticals, Inc. has a 12 month low of $96.18 and a 12 month high of $145.41.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.56 EPS for the quarter, beating the Zacks’ consensus estimate of $1.08 by $0.48. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The company had revenue of $912 million for the quarter, compared to the consensus estimate of $846.15 million. During the same period in the prior year, the firm posted $1.13 EPS. The company’s quarterly revenue was up 21.1% compared to the same quarter last year. Analysts forecast that Alexion Pharmaceuticals, Inc. will post $5.60 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark law. The original version of this piece of content can be viewed at https://www.watchlistnews.com/river-mercantile-asset-management-llp-has-464000-stake-in-alexion-pharmaceuticals-inc-alxn/1529605.html.

A number of research analysts recently issued reports on ALXN shares. BMO Capital Markets restated an “outperform” rating and set a $158.00 price target on shares of Alexion Pharmaceuticals in a report on Wednesday, May 24th. Raymond James Financial, Inc. restated a “strong-buy” rating and set a $176.00 price target on shares of Alexion Pharmaceuticals in a report on Tuesday, May 9th. Goldman Sachs Group, Inc. (The) restated a “buy” rating and set a $142.00 price target on shares of Alexion Pharmaceuticals in a report on Friday, June 9th. Zacks Investment Research upgraded Alexion Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $158.00 price target on the stock in a report on Wednesday, August 2nd. Finally, Leerink Swann restated a “buy” rating on shares of Alexion Pharmaceuticals in a report on Tuesday, May 23rd. Six equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. Alexion Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $156.13.

In other news, CEO Ludwig Hantson acquired 10,000 shares of the company’s stock in a transaction on Wednesday, June 14th. The shares were bought at an average cost of $116.72 per share, with a total value of $1,167,200.00. Following the transaction, the chief executive officer now owns 38,725 shares in the company, valued at approximately $4,519,982. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Ann M. Veneman sold 700 shares of the stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $137.74, for a total transaction of $96,418.00. Following the completion of the sale, the director now directly owns 6,315 shares in the company, valued at $869,828.10. The disclosure for this sale can be found here. Over the last three months, insiders acquired 2,019,734 shares of company stock worth $235,606,846. Insiders own 4.35% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.